In addition, ccRCC patients with a lower FDX1 gene expression have a shorter survival time (Figures 4A–C), probably due to the survival advantage of these tumor cells by resisting copper-induced toxicity. The gene discussed is FDX1; the disease is nonpapillary renal cell carcinoma.